Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate REGENXBIO Inc. before investing.

In this article, we go over a few key elements for understanding REGENXBIO Inc.’s stock price such as:

• REGENXBIO Inc.’s current stock price and volume
• Why REGENXBIO Inc.’s stock price changed recently
• Upgrades and downgrades for RGNX from analysts
• RGNX’s stock price momentum as measured by its relative strength

About REGENXBIO Inc. (RGNX)

Before we jump into REGENXBIO Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Want to learn more about REGENXBIO Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about REGENXBIO Inc..

REGENXBIO Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, REGENXBIO Inc.’s stock price was $9.690.

REGENXBIO Inc. is down 4.25% from its previous closing price of $10.120.

During the last market session, REGENXBIO Inc.’s stock traded between $9.635 and $10.380. Currently, there are approximately 52.43 million shares outstanding for REGENXBIO Inc..

REGENXBIO Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

REGENXBIO Inc. Stock Price History

REGENXBIO Inc.’s (RGNX) price is currently down 19.12% so far this month.

During the month of July, REGENXBIO Inc.’s stock price has reached a high of $15.880 and a low of $8.420.

Over the last year, REGENXBIO Inc. has hit prices as high as $16.190 and as low as $5.455. Year to date, REGENXBIO Inc.’s stock is down 32.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused REGENXBIO Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded REGENXBIO Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate REGENXBIO Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on REGENXBIO Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

REGENXBIO Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about REGENXBIO Inc. (RGNX) by visiting AAII Stock Evaluator.

Relative Price Strength of REGENXBIO Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, REGENXBIO Inc. has a weighted four-quarter relative price strength of 1.71%, which translates to a Momentum Score of 59 and is considered to be Average.

Want to learn more about how REGENXBIO Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

REGENXBIO Inc. Stock Price: Bottom Line

As of July 31, 2026, REGENXBIO Inc.’s stock price is $9.690, which is down 4.25% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like REGENXBIO Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.